Gilead Sciences, Inc. (ETR: GIS)

Market Cap	111.22B
Revenue (ttm)	25.37B
Net Income (ttm)	112.97M
Shares Out	n/a
EPS (ttm)	0.09
PE Ratio	984.48
Forward PE	n/a
Dividend	2.85 (3.18%)
Ex-Dividend Date	Dec 13, 2024

Volume	1,348
Average Volume	1,242
Open	89.11
Previous Close	89.72
Day's Range	88.59 - 89.90
52-Week Range	57.29 - 92.80
Beta	0.19
RSI	53.16
Earnings Date	Feb 3, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 18,000
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: GIS

Financial Performance

In 2023, Gilead Sciences's revenue was $27.12 billion, a decrease of -0.60% compared to the previous year's $27.28 billion. Earnings were $5.67 billion, an increase of 23.37%.

Financial numbers in USD